Special Issue "Molecular Diagnosis and Novel Therapies for Neuromuscular/Musculoskeletal Diseases"
A special issue of Journal of Personalized Medicine (ISSN 2075-4426).
Deadline for manuscript submissions: closed (31 October 2018)
Dr. Toshifumi Yokota
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, 8812-112 St. Edmonton, AB T6G 2H7, Canada
Website | E-Mail
Interests: neuromuscular disease; Duchenne/Becker muscular dystrophy; antisense therapy; animal models; spinal muscular atrophy; limb-girdle muscular dystrophy; Miyoshi myopathy
Dr. Rika Maruyama
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta
Interests: musculoskeletal disease; facioscapulohumeral muscular dystrophy (FSHD); CRISPR/Cas9 genome-editing; BMP signaling; Fibrodysplasia Ossificans Progressiva (FOP)
This Special Issue, “Molecular Diagnosis and Novel Therapies for Neuromuscular/Musculoskeletal Diseases”, will focus on the recent progress of molecular diagnosis and the development of novel therapies for neuromuscular and musculoskeletal diseases. We intend to invite researchers in the field to submit original research and review articles on the advancement of molecular diagnosis and novel therapies, including (but not limited to) molecular-based genetic tests, genome-wide association studies (GWAS), biomarkers, antisense oligonucleotide therapy, mutation-based therapy, gene therapy, molecular therapy, genome-editing technology, delivery enhancement, exosome-mediated delivery, stem cell transfer, and neuromuscular/musculoskeletal disease models to evaluate the efficacy of treatments. In addition, the mechanism involved in molecular diagnosis and novel therapies, such as genetic modifiers and stem cell functions, will be considered.
Prof. Toshifumi Yokota
Dr. Rika Maruyama
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Muscular dystrophy
- Neuromuscular/musculoskeletal disease
- Duchenne/Becker muscular dystrophy
- Antisense therapy
- RNA therapeutics
- Spinal muscular atrophy
- New chemistry for antisense therapy and genome-targeting
- New techniques of delivery for antisense therapy and genome-targeting